Avidity Partners Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Avidity Partners Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-172,000	Closed	-$49.7M	–	94
2022 Q4	$49.7M	Sell	172,000 -340,800	-66%	-$104M	1.08%	31
2022 Q3	$148M	Sell	512,800 -280,200	-35%	-$80.6M	3.02%	8
2022 Q2	$223M	Buy	793,000 +247,400	+45%	+$66.2M	5.13%	2
2022 Q1	$142M	Buy	545,600 +265,600	+95%	+$63M	2.96%	11
2021 Q4	$61.5M	Sell	280,000 -646,400	-70%	-$126M	1.3%	28
2021 Q3	$168M	Sell	926,400 -23,600	-2%	-$4.61M	3.72%	6
2021 Q2	$192M	Buy	950,000 +639,100	+206%	+$134M	5.18%	1
2021 Q1	$66.8M	Buy	310,900 +163,600	+111%	+$35.9M	1.85%	16
2020 Q4	$34.8M	Buy	+147,300	New	+$33.8M	1.13%	33
2020 Q2	–	Sell	-34,000	Closed	-$8.09M	–	77
2020 Q1	$8.09M	Sell	34,000 -6,000	-15%	-$1.38M	1.12%	32
2019 Q4	$8.76M	Buy	+40,000	New	+$8.1M	5.52%	3

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's VRTX Position: Q1 2023 in Review

Avidity Partners Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 172,000 shares — an estimated $49.7M sold.

Avidity Partners Management first reported a position in VRTX in Q4 2019 and held it in 11 quarters. The position peaked at $223M in Q2 2022. 1,208 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Avidity Partners Management reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Avidity Partners Management sold 172,000 Vertex Pharmaceuticals shares in Q1 2023, an estimated $49.7M.
Avidity Partners Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Avidity Partners Management's Vertex Pharmaceuticals position peaked at $223M in Q2 2022.
1,208 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.